Forty-two patients (91.3%) experienced treatment-related AEs (TRAEs), the most common being anemia (32.6%), elevated α-hydroxybutyrate dehydrogenase (28.3%) and elevated alanine aminotransferase (26.1%). This evidence concerns the gene GPT and anemia.